EMA Authorised: Rydapt (Midostaurin) — Novartis Europharm Ltd

View source ↗

Summary

The European Medicines Agency authorised Rydapt (midostaurin) for additional indications in acute myeloid leukemia and systemic mastocytosis. The decision inclu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Systemic Mastocytosis

Drugs mentioned

• Rydapt (midostaurin)

Snippet

Status: Authorised. Therapeutic area: Leukemia, Myeloid, Acute;Mastocytosis. MAH: Novartis Europharm Ltd. Decision date: 13/01/2026. Orphan medicine